Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrik Jonsson | M | 57 | 34 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Lechleiter | M | 70 | 38 years | |
| Stephen Sherwin | M | 75 |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA.
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 23 years |
| Jeffrey Ostrove | M | - |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | - |
| Randall L. Tobias | M | - | 12 years | |
| Bryce D. Carmine | M | 72 | 29 years | |
| Sharon Tetlow | F | 64 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| R. Greer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 5 years |
| Karen N. Horn | M | 80 | 29 years | |
| Inder Mohan Verma | M | 76 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA.
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Keith E. Brauer | M | 75 | 6 years | |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Robert H. Tidwell | M | 80 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 26 years |
| Mitchell Finer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 10 years |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Rolf K. Hoffmann | M | 64 | 17 years | |
| Anne Nobles | M | 67 | 22 years | |
| Frank M. Deane | M | 74 | 26 years | |
| Kate van Riper | F | - |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | - |
| Richard Pilnik | M | 67 | 25 years | |
| Diana McKenzie | F | 59 | 12 years | |
| Michael Harrington | M | 61 | 29 years | |
| Gregory Davis | M | 70 | 20 years | |
| James Cornelius | M | 81 | 12 years | |
| David Warren Carter | M | 84 |
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA.
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Deirdre Connelly | F | 63 | 26 years | |
| Mark D. Miles | M | 70 | 2 years | |
| Sharon L. Sullivan | F | - | - | |
| Lisa Guttman | F | - | 10 years | |
| Jeffrey Simmons | M | 56 | 29 years | |
| Fionnuala M. Walsh | M | 64 | 29 years | |
| Albertus van den Bergh | M | - | - | |
| Jacques Tapiero | M | 66 | 31 years | |
| Peter James Johnson | M | - | - | |
| T. Spencer Williamson | M | - | 3 years | |
| Timothy Franson | M | 72 | 22 years | |
| Johanna Carmel Egan | M | - | - | |
| Robert A. Cole | M | - | - | |
| Arnold Hanish | M | 76 | 28 years | |
| David Mullarkey | M | 57 | - | |
| Simon Harford | M | 63 | - | |
| A. Jay Graf | M | - | 14 years | |
| Marc M. P. de Garidel | M | 66 | 12 years | |
| Thomas Bumol | M | 70 | 35 years | |
| David Gonyer | M | 60 | 9 years | |
| Mohammed Khoso Baluch | M | 66 | 24 years | |
| Peter Wege | M | 75 | 6 years | |
| Natalie Sacks | M | 59 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Michael R. Meadows | M | - | 35 years | |
| Chuan Shih | M | - | - | |
| A. Lynn Daniel | M | - | 3 years | |
| Curtis Oltmans | M | 60 | 13 years | |
| Michael W. Ramsay | M | 67 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 6 years |
| Thomas W. Grein | M | 72 | 41 years | |
| Bruno Boulanger | M | - | - | |
| Pei-Chien Sun | M | - | 1 years | |
| Stephen F. Fry | M | 58 | 35 years | |
| Peter K. Working | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 years |
| Shirley M. Clift | F | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 years |
| Steven R. Gailar | M | - | 14 years | |
| W. Darin Moody | M | - | - | |
| Ford R. Lynch | M | 77 | 11 years | |
| Neal Fowler | M | 62 | 13 years | |
| Roger Marchetti | M | 65 | - | |
| John E. Voris | M | 76 | 22 years | |
| Guido Neels | M | 75 | 12 years | |
| David A. Broecker | M | 63 | 16 years | |
| Robert Zerbe | M | 73 | 11 years | |
| William Ringo | M | 78 | 28 years | |
| Robert Davis | M | 57 | 14 years | |
| Richard DiMarchi | M | 71 | 11 years | |
| Robert J. Dow | M | 73 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 years |
| Brett L. Schmidli | M | 72 | 10 years | |
| Michael E. Hanson | M | 74 | 24 years | |
| Pierre V. Trân | M | 64 | 12 years | |
| Frederick W. Ruebeck | M | 85 | 11 years | |
| Anthony John Murphy | M | 73 | 29 years | |
| Carol Gallagher | M | 59 | 8 years | |
| Jeffrey Steven Silverman | M | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 2 years |
| Ronald W. Dollens | M | 77 | 3 years | |
| Michael C. Heim | M | 69 | - | |
| Barry I. Eisenstein | M | 75 | 6 years | |
| John W. Price | M | 79 | 17 years | |
| Homer Pearce | M | 71 | 27 years | |
| Lesley A. Stolz | M | 60 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 1 years |
| Martin F. Haslanger | M | - | 9 years | |
| Karl E. White | M | - | 4 years | |
| Jerome H. Fleisch | M | - | 27 years | |
| Gino Santini | M | 67 | 27 years | |
| B. Jack Miller | M | - | 19 years | |
| William L. Lister | M | - | 13 years | |
| John T. Boris | M | - | 10 years | |
| Patricia Martin | F | 63 | 26 years | |
| Joseph Zakrzewski | M | 60 | 16 years | |
| Gary D. Tollefson | M | 72 | 13 years | |
| Charles Schalliol | M | 76 | 25 years | |
| John E. Ezcurra | M | - | 2 years | |
| Paul F. Banta | M | 63 | 8 years | |
| Scott Jackson | M | 59 | 5 years | |
| Denice Torres | F | 64 | 14 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eugene L. Step
- Personal Network
